One2Treat reflects patient priorities in a
single multi-facet treatment assessment, reducing trial sample size
and accelerating patient access to new treatments.
BRUSSELS, July 9, 2024 /PRNewswire/ -- In this new
role, Dr. Piedbois will ensure the One2Treat suite of
offerings are developed and delivered with the requirements of both
patients, and the sponsor's clinical teams, front and
center.
One2Treat's innovative approach, driven by its Founder
Marc Buyse, aims to reduce
trial sample sizes and accelerate patient access to new treatments.
One2Treat software helps incorporate multiple clinical outcomes
that matter to the patient as early as the study design through
robust statistical methodologies. Dr. Pascal Piedbois will
be a key driver in this endeavor.
Dr. Pascal Piedbois, Prof. of Medical Oncology,
brings over 30 years of clinical development experience in both
academia and industry, holding positions including Head of Medical
Oncology at Paris University,
General Director of the Comprehensive Cancer Center of Alsace
Region, and several leadership roles in the pharmaceutical
industry, including Vice President, Head of Global Oncology and
Infectious Diseases at AstraZeneca, Senior Vice President, Medical
Head Major Markets at Bristol Myers Squibb and General Manager at
Boehringer-Ingelheim Belgium.
"Pascal's extensive medical experience will address one
of the most strategic challenges in the biopharma industry today:
incorporating multiple patient-relevant outcomes into a single
holistic treatment assessment," said Sebastien Coppe, CEO of One2Treat.
"In today's clinical studies, focusing on one or two primary
endpoints often leads to underutilization of valuable data and
fails to capture the holistic impact of treatments on patients.
Pascal's deep industry knowledge will ensure that our
innovative solutions bring clinically meaningful transformations in
the way we design clinical trials."
Dr. Pascal Piedbois adds: "There is a huge opportunity to
involve patients, sponsors, regulatory agencies, and payers early
in the clinical trial design process. By aligning on their specific
needs and prespecifying the primary endpoint of the registration
study, we can run more efficient trials and bring new treatments to
market faster. This approach will ensure that clinical trials are
more reflective of what truly matters to patients, including
quality of life for instance."
Marc Buyse, Founder of
One2Treat, highlights the need for a more patient-centric
approach in clinical research: "I am delighted
that Pascal, with whom I have had a long and very
fruitful collaboration, joins One2Treat today. His medical
expertise will speed up the implementation of this
multi-dimensional approach, ensuring our message resonates with
medical leaders."
Dr. Pascal Piedbois concludes: "One2Treat's
innovative approach also facilitates a more transparent and
efficient transition from drug development to market access. Using
a rigorous, quantitative method to analyze overall treatment
effects allows us to connect clinical research and health
technology (HTA) assessment seamlessly, providing a comprehensive
benefit-risk assessment based on what matters most to
patients."
For more information on One2Treat and its
paradigm shifting solution, visit www.one2treat.com
and join the movement towards patient-centric
healthcare.
About One2Treat:
One2Treat is a forward-thinking partner for
biopharmaceutical companies, dedicated to delivering transformative
insights in clinical trial design, analysis, and market access
evaluations to support holistic treatment
decisions.
Driven by a commitment to patient-centricity,
One2Treat leverages modern statistical methodologies and
advanced software solutions to integrate multiple specific efficacy
and safety outcomes into a single aggregated measure. This approach
allows for the estimation of the Net Treatment Benefit based on
patients' preferences, ushering in a new era of personalized
healthcare.
One2Treat's unique solution empowers sponsors
to optimize the design of registration trials, by incorporating
multiple patient-relevant outcomes in a single primary analysis,
resulting in smaller sample sizes and more clinically relevant
analyses. This leads to significantly shorter recruitment timelines
and improved biopharma R&D productivity. Additionally,
One2Treat facilitates market access through comprehensive
benefit-risk assessments and patient-centric analyses, aligning
with the evolving landscape of healthcare needs.
As initiatives to incorporate patients' preferences into
treatment development continue to gain momentum, the adoption
of One2Treat's innovative multi-facet trial designs is
poised to become the new gold standard in the
industry.
To learn more about how One2Treat is revolutionizing
treatment decisions in clinical research and market access,
visit: www.one2treat.com.
View original
content:https://www.prnewswire.co.uk/news-releases/pascal-piedbois-md-phd-joins-one2treat-as-chief-medical-officer-to-advance-patient-centric-innovation-in-clinical-trial-design-and-market-access-302192054.html